You are here

A piece of news

More than twenty biotech and pharmaceutical companies from Catalonia to participate in partnering at BIO-Europe Vienna

The congress, from 4 to 6 November, will receive 3,200 executives and investors mainly from Europe and North America.

AddToAny buttons: 

By Biocat

The benchmark European partnering congress in biotechnology and pharmaceuticals, BIO-Europe will host 22 companies from Catalonia from 4 to 6 November 2013 in Vienna (Austria), a significant delegation equal in size to that of the previous edition. There will be 53 companies from Spain, in addition to the Spanish Bioindustry Association (Asebio) and Invest in Spain.

The Catalan companies participating in BIO-Europe Vienna to scout for partners, collaboration on their research projects and licensing opportunities are: Ability Pharmaceuticals, Advancell, Almirall, Anaxomics, Asphalion, Ernst & Young, Ferrer Internacional, Gebro Pharma, InKemia IUCT Group, Intelligent Pharma, Iproteos, Janus Developments, Kymos Pharma Services, Lacer, Minoryx Therapeutics, Grup Reig Jofré, Sagetis Biotech, SOM Biotech, STAT-Diagnostica, Thrombotargets Europe, Uquifa and Ysios Capital.

This will be the nineteenth edition of BIO-Europe, organized by EBD Group with collaboration from the Biotechnology Industry Organization (BIO) of the United States. The event expects to welcome some 3,200 delegates from 1,800 companies. In 2012, 66% of visitors were from Europe, 19% from North America, 11% from Asia and 4% from the rest of the world.

The spring edition, BIO-Europe Spring 2013, was held in Barcelona with Biocat and the Barcelona City Council.

The highlight of the congress is the one-to-one meetings as the figures show: more than 15,000 held in 2012. There is also a program of lectures, panel discussions and workshops, business presentations —from Catalonia, Ability Pharmaceuticals, Almirall, Ferrer Internacional and STAT-Diagnostica have been selected— and an exhibition area.

Program highlights include Tony Coles, former chairman and CEO of Onyx Pharmaceuticals, who will give the keynote address explaining the history and evolution of this leading oncology company through acquisition by its main competitor, Amgen, in August 2013, for USD $10.4 billion.

Coles will also participate in the plenary session entitled How can R&D strategy influence patient outcomes? with M. Johnston Erwin, vice president of Strategy and Operations for Eli Lilly; Susan Jane Herbert, executive vice president of Global Business Development for Merck Serono; and Maya Said, head of Strategy, Science Policy and External Innovation for Sanofi.

New at this edition of BIO-Europe is the Academic Innovators Showcase, which aims to encourage participation from researchers at universities, hospitals and research centers.

Follow the congress on Twitter with the hashtag #BEU13.

Date: 4 to 6 November 2013
Venue: Messe Wien Exhibition and Congress Center • Vienna (Austria)

One-to-one partnering meetings at BIO-Europe Spring Barcelona last march - Photo: © EBD Group.